ArticleCureus2025
Endobronchial Valves for Recurrent Hemoptysis Secondary to Aspergilloma: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Superselective Pulmonary Artery Embolization for Refractory Massive Hemoptysis Post-Bronchial Artery Embolization: A Bail-Out Measure.Cardiovascular and interventional radiology · 2026Article
- Management of airway hemorrhage with endobronchial valve in patients undergoing pulmonary endarterectomy- an expert center experience: a case report.BMC anesthesiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspergilloma is a common cause of hemoptysis and can result in significant morbidity and mortality in patients with structural lung disease. While surgical resection is the gold standard for treating aspergilloma, many patients are not suitable candidates for surgery. In this report, we explore the use of endobronchial valves (EBVs) as a non-surgical alternative for managing recurrent hemoptysis in a patient with interstitial lung disease (ILD) and a left upper lobe aspergilloma. Despite previous treatments, including antifungals and radiation, the patient experienced persistent hemoptysis and was not a candidate for either bronchial artery embolization or lobectomy. An EBV was implanted in the affected lung segment, resulting in the resolution of the hemoptysis without valve-related complications on the six-month follow-up. While the use of EBVs for hemoptysis management has been reported in a few cases, this is, to our knowledge, the first report in a patient with ILD. This approach presents a viable non-surgical alternative in complex cases where conventional treatments have proven ineffective or are not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.